US 8691501
Farnesyltransferase inhibitors for treatment of laminopathies, cellular aging and atherosclerosis
granted A61KA61K31/4545A61K31/4709
Quick answer
US patent 8691501 (Farnesyltransferase inhibitors for treatment of laminopathies, cellular aging and atherosclerosis) held by The United States of America as Represented by the Secretary of the Department of Health and Human Services expires Mon Apr 03 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The United States of America as Represented by the Secretary of the Department of Health and Human Services
- Grant date
- Tue Apr 08 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Apr 03 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 4
- CPC classes
- A61K, A61K31/4545, A61K31/4709, A61K45/06, A61P